Bausch+Lomb Results Presentation Deck
Delivering on Areas of Key Focus in 2022
Continue momentum
in current portfolio
Invest in categories
growing faster than
market
Expand into new
product categories
BAUSCH + LOMB
4-5% organic revenue growth in FY22 expected ¹.2
Strong performance in key franchises: Ocuvite® + PreserVision®, LUMIFY®, Artelac®, Bio TrueⓇ
Global Mega Brand and core vision care brands (BioTrue® ONEday, Bausch + Lomb ULTRA®,
Daily SiHy)
Geo-expansion and line extensions in numerous key franchises
Market share gains seen across key franchises
Continued rollout of Daily SiHy
Strong performance in implantables, following premium IOL rollout
Planning for upcoming launch of 3D microscope
FDA filing acceptance of NOV03 (PDUFA date June 2023)
Launched XIPERE® and positive early results
Launched Revive ™ Custom Soft Contact lenses
Launched Project Watson ™ health care product for dogs
Entered into an exclusive European distribution agreement for MIMS® minimally invasive
surgical procedure for treatment of glaucoma
Enrolled first patient in LASIK clinical trial for Technolas® TENEO™ Excimer Laser
1. This is a non-GAAP measure or ratio. See Slide 2 and Appendix for further information on non-GAAP measures or ratios. See slides 10 and 11 for disclosure of historic non-GAAP measures and ratios and their historic comparable GAAP measures and ratios.
2. The guidance in this presentation is only effective as of the date given, Nov. 2, 2022, and will not be updated or affirmed unless and until the Company publicly announces updated or affirmed guidance. Distribution or reference of this deck following Nov. 2, 2022
does not constitute the Company re-affirming guidance. See Slide 1 for further information on forward-looking statements.
23View entire presentation